Serial HRCT Lung Changes after 3-Field Radiation Treatment of Breast Cancer

Ooi, G. C.; Kwong, Dlw; Chan, K N; Ngan, Hextan Y.S.; Lock, Derrick; Lam, Wah‐Kit; Chan, F. L.; Au, Gordon K.H.; Tsang, Kenneth W.

doi:10.1053/crad.2000.0542

Cited by 17 publications

(13 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Schratter-Sehn and group reported no normal finding in plain radiographs although all patients evinced changes in HRCT [15]. Ooi and associates reported that all their 30 patients yielded HRCT findings at three months after radiotherapy and the situation was the same up to one year [31]. Score-4 lesions, honeycombing areas, were seen in 3 patients, all mild reactions in our study.…”

Section: Discussioncontrasting

confidence: 39%

Radiological pulmonary findings after breast cancer irradiation: A prospective study

Järvenpää¹,

Holli²,

Pitkänen³

et al. 2006

Acta Oncologica

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 39%

Radiological pulmonary findings after breast cancer irradiation: A prospective study

Järvenpää¹,

Holli²,

Pitkänen³

et al. 2006

Acta Oncologica

View full text Add to dashboard Cite

“…Specific applications of ultrasound "lung comet" for CT monitoring has not yet reported but in our clinical practice it can be visualized particularly in oncologic patients who experienced radiation therapy (Figure 6). In these cases it might be considered a sign of alveolar-capillary membrane distress (ARDS-like syndrome), already demonstrated by other imaging techniques and due to acute, deterministic, combined radiation and chemo-therapy [98,99]. …”

Section: Advanced Ultrasound Tools For Early Detection Of Cardiotoxicitymentioning

confidence: 99%

Cancer therapy and cardiotoxicity: The need of serial Doppler echocardiography

Galderisi

Marra

Esposito

et al. 2007

Cardiovasc Ultrasound

View full text Add to dashboard Cite

Cancer therapy has shown terrific progress leading to important reduction of morbidity and mortality of several kinds of cancer. The therapeutic management of oncologic patients includes combinations of drugs, radiation therapy and surgery. Many of these therapies produce adverse cardiovascular complications which may negatively affect both the quality of life and the prognosis. For several years the most common noninvasive method of monitoring cardiotoxicity has been represented by radionuclide ventriculography while other tests as effort EKG and stress myocardial perfusion imaging may detect ischemic complications, and 24-hour Holter monitoring unmask suspected arrhythmias. Also biomarkers such as troponine I and T and B-type natriuretic peptide may be useful for early detection of cardiotoxicity. Today, the widely used non-invasive method of monitoring cardiotoxicity of cancer therapy is, however, represented by Doppler-echocardiography which allows to identify the main forms of cardiac complications of cancer therapy: left ventricular (systolic and diastolic) dysfunction, valve heart disease, pericarditis and pericardial effusion, carotid artery lesions. Advanced ultrasound tools, as Integrated Backscatter and Tissue Doppler, but also simple ultrasound detection of "lung comet" on the anterior and lateral chest can be helpful for early, subclinical diagnosis of cardiac involvement. Serial Doppler echocardiographic evaluation has to be encouraged in the oncologic patients, before, during and even late after therapy completion. This is crucial when using anthracyclines, which have early but, most importantly, late, cumulative cardiac toxicity. The echocardiographic monitoring appears even indispensable after radiation therapy, whose detrimental effects may appear several years after the end of irradiation.

show abstract

“…Other groups have seen correlation between functional and radiological radiation-induced damage. Oii et al [22] observed a significant decline in lung function with increased lung injury score in high resolution CT images for 30 BC patients. Lind et al [23] reported a significant different decrease in vital capacity between patients with low and high scores of CT-changes (modified Arriagada classification) 4 months after completion of treatment for 105 breast cancer (BC) patients.…”

Section: Discussionmentioning

confidence: 98%